Form 4: Indivior CFO's Routine Stock Vesting and Tax Withholding

Indivior Pharmaceuticals CFO Ryan Preblick reported the vesting of performance stock units and subsequent tax-related share withholding.

Summary

• Indivior Pharmaceuticals CFO Ryan Preblick reported two transactions on March 3, 2026, related to his beneficial ownership.
• 87,597 shares of Common Stock were withheld to satisfy tax obligations at a price of $31.98 per share. These shares originated from performance stock units granted in 2021, which vested in 2024 and completed a two-year holding period.
• 86,949 shares of Common Stock were acquired due to the vesting of performance stock units granted in 2023. The performance conditions for these units were met at 76.6% of the target 113,510 units.
• The newly acquired 86,949 shares are subject to a further two-year holding period.
• Following these transactions, Ryan Preblick directly beneficially owns 317,292 shares of Indivior Pharmaceuticals Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the vesting of performance stock units indicates the achievement of performance conditions, reflecting positively on the company's operational execution. However, the transactions are largely routine compensation events.

Positives

• Performance conditions for the 2023 performance stock units were met at 76.6%, leading to the vesting of 86,949 shares, indicating successful achievement of company targets.

Future Outlook

The 86,949 shares acquired from the 2023 PSU vesting are subject to a further two-year holding period, indicating they will be released following March 3, 2028.

Industry Context

StockSavvy.ai notes that insider transaction filings like Form 4 provide transparency into executive compensation and ownership. While these specific transactions relate to pre-scheduled vesting and tax obligations rather than discretionary open-market purchases or sales, the achievement of performance conditions for the PSUs reflects positively on the company's operational execution within the pharmaceutical industry.

Stakeholder Impact

• Shareholders: Increased transparency regarding executive compensation and ownership. The vesting of performance stock units suggests that performance targets were met, which could be viewed positively as an indicator of company performance.
• Employees: The filing demonstrates that standard executive compensation practices, including performance-based awards and holding periods, are being followed.

Next Steps

• The 86,949 shares from the 2023 PSU vesting will be released following a two-year holding period, which concludes after March 3, 2028.

Key Dates

Recommendation

This Form 4 details routine executive compensation events, specifically the vesting of performance stock units and subsequent tax withholding. While the vesting indicates performance conditions were met, these are pre-scheduled transactions and do not provide new fundamental information to warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for significant price movement.

Keywords

Indivior Pharmaceuticals, INDV, Ryan Preblick, CFO, Form 4, Insider Transaction, Stock Vesting, Performance Stock Units, Tax Withholding, Beneficial Ownership